Clinical significance of immunogenic cell death biomarker rage and early growth response 1 in human primary gastric adenocarcinoma

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 2, 2013, Pages 485-493

  Xu, X C ^a   Gao, H ^a   Zhang, W B ^a   Abuduhadeer, X ^a   Wang, Yun Hai ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Early growth response 1; Gastric cancer; Metastasis; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; EARLY GROWTH RESPONSE FACTOR 1;

ADJACENT NON CANCER TISSUE; ADULT; ARTICLE; CANCER PATIENT; CANCER TISSUE; CELL DEATH; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TISSUES; TUMOR LOCALIZATION; TUMOR VOLUME; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL FEATURE; DOWN REGULATION; PANCREAS CANCER; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION;

EID: 84881252709     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600222     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Tajima Y, Yamazaki K, Makino R, et al. Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 2006; 12:6469-79. (Pubitemid 44799720)
3. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004; 51:928-30. (Pubitemid 38822439)
4. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin, are overexpressed and associated with prostate cancer development. Prostate 2005; 64:92-100. (Pubitemid 40734743)
5. Lin L, Zhong K, Sun Z, Wu G, Ding G. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 2012; 138:11-22.
6. Kang R, Tang D, Schapiro NE, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17:666-76.
7. Kang R, Tang D, Lotze MT, Zeh HJ 3rd. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 2012; 8:989-91.
8. Dergunoa LV, Raevskaia NM, Volosheniuk EL, Limborskaia SA. Expression peculiarities of EGR1, neurotrophins and their receptor genes in human lung cancer and in normal lung tissue. Mol Gen Mikrobiol Virusol 2007; 2:25-30.
9. Di Loreto C, Tell G, Pestrin M, Pandolfi M, Damante G, Puglisi F. PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 2005; 224:105-9. (Pubitemid 40720371)
10. Liu J, Liu YG, Huang R, et al. Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. Cancer Genomics Proteomics 2007; 4:377-85.
11. Gibbs JD, Liebermann DA, Hoffman B. Leukemia suppressor function of Egr-1 is dependent on transforming oncogene. Leukemia 2008; 22:1909-16.
12. Lee KH, Kim JR. Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells. Clin Exp Metastasis 2009; 26:685-92.
13. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010; 337:251-8.
14. Kang R, Loux T, Tang D, et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci USA 2012; 109:7031-6.
15. Heijmans J, Büller NV, Hoff E, et al. Rage signalling promotes intestinal tumourigenesis. Oncogene 2012. doi: 10.1038/onc.2012.119. [Epub ahead of print]
16. Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 2010; 57:55-61.
17. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:1430-8.
18. Tateno T, Ueno S, Hiwatashi K, et al. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16:440-6.
19. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196:163-70. (Pubitemid 34110897)
20. Lucerna M, Pomyje J, Mechtcheriakova D, et al. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res 2006; 66:6708-13. (Pubitemid 44085628)
21. Bouchard F, Bélanger SD, Biron-Pain K, St-Pierre Y. EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth. Blood 2010; 116:759-66.
22. Kataoka F, Tsuda H, Arao T, et al. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy. Genes Chromosomes Cancer 2012; 51:300-12.
23. Yang SZ, Eltoum IA, Abdulkadir SA. Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment. J Cell Biochem 2006; 97:1292-9.
24. Parra E, Ferreira J. The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. Oncol Rep 2010; 23:1159-65.
25. Zheng L, Pu J, Jiang G, et al. Abnormal expression of early growth response 1 in gastric cancer: association with tumor invasion, metastasis and heparanase transcription. Pathol Int 2010; 60:268-77.